Erratum

AST2818 is at the stage of drug registration in China. The name of ‘Alflutinib’ was changed as per the requirements of the National Pharmacopoeia Committee of China and the “China drug generic naming principle”, and it has been confirmed that the name of the drug has been changed from ‘Alflutinib’ to ‘Furmonertinib’. Therefore, as the corresponding author of this article, I specially inform you that ‘Alflutinib’ has been changed to ‘Furmonertinib’. My research team and I solemnly promise that they are the same drug. In future, the name ‘Furmonertinib’ will be applied in all the following studies and publications.